Abstracts tagged "rheumatoid arthritis (RA) and tumor necrosis factor (TNF)"

Abstract Number: 347 • 2012 ACR/ARHP Annual Meeting
The Loss of S100A4 Prevents Induction of Experimental Arthritis in Human Tumour Necrosis Factor Transgenic Mouse Model
Michal Tomcik¹, Christine Boehm², Carina Scholtysek³, Lucie Andres Cerezo⁴, Wolfgang Baum³, Clara Dees³, Christian Beyer³, Jerome Avouac⁵, Pawel Zerr³, Katrin Palumbo-Zerr³, Alfiya Akhmetshina³, Radim Becvar¹, Oliver Distler⁶, Mariam Grigorian⁷, Gerhard Kroenke³, Georg A. Schett⁸, Joerg HW Distler³ and Ladislav Senolt¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Paris Descartes University and INSERM U1016, Rheumatology A department, Cochin Hospital, Paris, France, ⁶Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Our previous study demonstrated increased levels of S100A4 protein in sera, synovial fluid and synovial membrane of patients with rheumatoid arthritis (RA) compared to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].